British Association of Dermatologists and British Photodermatology Group Guidelines for the Safe and Effective Use of Psoralen–Ultraviolet A Therapy 2015

T.C. Ling; T.H. Clayton; J. Crawley; L.S. Exton; V. Goulden; S. Ibbotson; K. McKenna; M.F. Mohd Mustapa; L.E. Rhodes; R. Sarkany; R.S. Dawe


The British Journal of Dermatology. 2016;174(1):24-55. 

In This Article

Introduction and History

PUVA has been in use with refined psoralens since the early 1950s.[4] Its use has declined somewhat as narrowband ultraviolet B (NB-UVB) replaced less effective broadband ultra-violet B (BB-UVB) sources to treat psoriasis, and as NB-UVB has been proved more effective than PUVA in treating vitiligo.[5,6] It remains an important treatment, being the first-line phototherapy for pityriasis rubra pilaris and plaque-stage mycosis fungoides (MF), and a good second-line phototherapy for common chronic dermatoses, including psoriasis (for which it may be more effective than other interventions such as the new biological therapies),[7] atopic eczema and chronic urticaria. For phototherapy units serving small populations the availability of NB-UVB should be the first priority, but all larger phototherapy units should be able to offer PUVA.